^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

S95024

i
Other names: S95024, Sym024, S-95024, S095024, S-095024, S 95024, Sym 024, Sym-024
Associations
Company:
Servier
Drug class:
CD73 inhibitor
Associations
7ms
Enrollment change • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021
7ms
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=100, Active, not recruiting, Symphogen A/S | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021
10ms
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=100, Active, not recruiting, Symphogen A/S | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021
1year
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=100, Active, not recruiting, Symphogen A/S | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021
over1year
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=100, Recruiting, Symphogen A/S | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021
over2years
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=100, Recruiting, Symphogen A/S | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
Trial completion date • Trial primary completion date • Combination therapy
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021
over3years
[VIRTUAL] Preclinical characterization of Sym024, a novel anti-CD73 antibody (AACR 2021)
In vitro one-way mixed lymphocyte reaction results demonstrate the utility of combining CD73 inhibition with PD-1 blockade, as Sym024 acts to reverse the immune suppressive effect of adenosine production, thereby allowing effective T cell activation by an anti-PD-1 antibody (Sym021). Dose-proportional and linear pharmacokinetics (PK) was observed at high dose levels while nonlinear PK became evident at lower exposure levels. Sym024 is currently under clinical investigation.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto) • CD4 (CD4 Molecule) • NT5E (5'-Nucleotidase Ecto) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
CD73 overexpression • CD73 expression • NT5E overexpression
|
S95024 • Sym021
almost4years
Clinical • New P1 trial • Combination therapy
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021